Mercado Global de Doenças de Huntington – Tendências e Previsão da Indústria para 2030

Análise e dimensão do mercado da doença de Huntington

A doença de Huntington afecta cerca de 30.000 pessoas na América do Norte, com uma taxa de prevalência de 5,7 por 100.000 pessoas. Não é tão comum nas crianças. Espera-se que a doença de Huntington testemunhe desenvolvimentos extensivos nos próximos anos, à medida que os medicamentos modificadores da doença transformam o panorama do mercado. As pesquisas mais recentes nesta condição centram-se principalmente na utilização de vários novos tratamentos, tais como terapias imunomoduladoras, terapia genética (utilizando oligonucleótidos anti-sentido, splicing de mRNA, micro RNAs (miRNA) e proteína de ligação ao ADN de dedo de zinco (ZFP) ).  

A Data Bridge Market Research analisa uma taxa de crescimento no mercado de doenças de Huntington no período de previsão 2023-2030. O CAGR esperado do mercado da doença de Huntington tende a rondar os 20,1% no período de previsão mencionado. O mercado foi avaliado em 434,7 milhões de dólares em 2022 e cresceria até 1.881,63 milhões de dólares até 2030. Além dos insights de mercado, tais como valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes no mercado e cenário de mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado da doença de Huntington

Market Definition

Huntington’s disease is a rare type of inherited disease which causes progressive breakdown  of nerve cells in the brain, majorly affecting physical movements, emotions and cognitive abilities. The symptoms associated with this disease can appear at any time but typically appear at 30-40 years old. If the condition appears before 20 years of age, this disorder is considered to be juvenile Huntington’s disease.

Huntington’s Disease Market Dynamics

Drivers

• Increasing Prevalence of Huntington’s Disease

Huntington’s Disease (HD) is a progressive neurological condition that is caused by CAG expansions in the Huntingtin (Htt) gene. It affects around 1 out of every 10,000 people in the U.S. Healthy people mostly have less than 35 CAG repetitions, on the other hand, HD patients have CAG expansions that ranges from 36 to 200. The frequency varies by more than 10-fold between different geographical locations, that can be associated to variations in case ascertainment and diagnostic criteria.  

• Growing Demand For Disease-Modifying Therapies

The disease-modifying therapies segment is projected to witness the huge growth during the forecast period. This is due to an increase in R&D for disease-modifying therapy and the rising demand for advanced products, such as gene therapy and stem cell therapy. The government initiatives such as Fast Track Designation by the U.S. FDA for increasing the registration process may surge the market in the upcoming years. For instance, in 2021 in the month of September, U.S. FDA granted fast track designation to Sage Therapeutics’s drug, SAGE-718, as a budding treatment for Huntington’s disease.

Opportunities

• Increased Clinical Research Activities

There have been growing clinical research activities for numerous drug development processes that are boosting the market's growth. For instance, Annexon, Inc. is engaged in the development of ANX005-an experimental monoclonal antibody that targets abnormal C1q activity in complement-mediated neurodegenerative diseases, such as huntington’s disease. This is administered intravenously (IV) and is meant to suppress C1q. Additionally, in November 2020, the company initiated a phase 2 clinical trial of ANX005 used for the treatment of HD patients. Stem cell therapy is also causing interest as a potential treatment for HD. Cellavita, in collaboration with AzidusPharma, is currently investigating stem cell therapy, CELLAVITA-HD in phase 2/ 3 ADORE-DH trial.   

• Increasing Drug Approvals

There have been growing drug approvals for the treatment of HD patients. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. received NMPA approval for Austedo in China for treating cholera associated with Huntington’s disease. This huge expansion of the company is anticipated to increase the patient base and the revenue growth.

 Restraints/Challenges

• Limited Availability of Drugs

The number of approved drugs for Huntington’s disease are limited because of strict policies and regulations. This is anticipated to impede the market growth during the forecast period. Furthermore, the lack of awareness about this disorder in major parts of the world is estimated to restrict the growth of huntington’s disease market.

• Discontinuation of Drug Trials

The drug development for the disease has faced severe obstacles as several therapies have failed to demonstrate efficacy or were related with major toxicity. For instance, in March 2021, F. Hoffmann-La Roche Ltd. discontinued the dosing in the phase III GENERATION HD1 study of tominersen in manifest HD. This conclusion was made on the basis of findings of an unblinded Independent Data Monitoring Committee's (iDMC) pre planned examination of data from the phase III research.

This Huntington’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Huntington’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Huntington’s Disease Market

During the COVID-19 pandemic, the sales of off-label drugs such as antipsychotics, anti-depressants, and anticonvulsant were done through numerous online pharmacies to manage symptoms associated with the disease. The conduction of clinical trials was delayed because of the government-imposed lockdown during the COVID-19 pandemic.

In the post pandemic era, many of hospitals and clinics worldwide reported that clinical visits frequency for the diagnosis and treatment of HD has improved. Consequently, the market will grow with the projected growth rate. The clinical trials for Huntington’s disease development have increased post-pandemic.

Recent Developments:

• In 2021, NeuExcell Therapeutics Inc collaborated with Spark Therapeutics, Inc. to develop gene therapy for the treatment of HD. Under the agreement, NeuExcell Therapeutics is meant to receive upfront license fees, R&D, and sales milestone payments of up to approximately USD 190 million and additional product royalties.

Global Huntington’s Disease Market Scope

The Huntington’s disease market is segmented on the basis of diagnosis, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• MRI
• CT Scan
• Genetic Testing
• Others

Treatment Type

• Symptomatic Therapy
• Disease-Modifying Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Huntington’s Disease Market Regional Analysis/Insights

The Huntington’s disease market is analyzed and market size insights and trends are provided by diagnosis, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the Huntington’s disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific will be expecting positive growth for Huntington’s disease market throughout the forecasted period due to the continuously increasing population resulting increasing prevalence of CNS related disorders.  

North America dominates the market due to increased demand of CNS disorders treatment and research undertaken by several companies.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Cenário competitivo e análise global da quota de mercado da doença de Huntington

O panorama competitivo do mercado da doença de Huntington fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados fornecidos acima estão apenas relacionados com o foco das empresas relacionado com o mercado da doença de Huntington.

Os principais players que trabalham no mercado da Doença de Huntington incluem:

• Teva Pharmaceutical Industries Ltd (Israel)
• Amneal Farmacêutica LLC. (NÓS)
• Elekta AB (Suécia)
• Alnylam Pharmaceuticals, Inc (EUA)
• Apotex Inc (Canadá)
• Armata Pharmaceuticals, Inc.
• Pfizer Inc (EUA)
• H. Lundbeck A/S (Dinamarca)
• Alterity Therapeutics (Austrália)
• Vertex Pharmaceuticals Incorporated (EUA)
• SK Plc. (REINO UNIDO)
• Ceregene, Inc (EUA)
• SOM BIOTECH (Espanha)
• Palobiofarma (Espanha)
• Ipsen Pharma (França)

SKU-59170